BXCL501 achieves primary efficacy endpoint in phase 3 TRANQUILITY II trial of Alzheimer agitation.

Published Date: 24 Sep 2023

In the Phase 3 TRANQUILITY II Alzheimer Agitation Trial, BXCL501 achieves the primary efficacy end point.

Read Full News

Latest News

Ocular Motor Cranial Neuropathy Tied to Parkinson’s Disease

Ocular motor cranial neuropathy is associated with an increased risk for Parkinson’s disease, a new study shows.

TBI Shows Two-Way Association With Neurologic Conditions

Traumatic brain injury is bidirectionally associated with the incidence of stroke, dementia, epilepsy, and Parkinson’s disease, a retrospective study shows.

Targeted Therapy Tied to Less Severe Auditory Hallucinations

Targeted interventions, especially avatar therapy, are associated with less severe auditory hallucinations in patients with schizophrenia, a new meta-analysis shows.

Novel, Adaptive DBS Tied to Fewer Falls in Parkinson’s

In a small feasibility study, a novel adaptive DBS system synchronized with the walking cycle has been shown to reduce the risk for falls among patients with Parkinson’s disease.

ECT Tied to Delayed Schizophrenia Rehospitalizations

Electroconvulsive therapy (ECT) is associated with longer time to hospital readmission or suicide compared to non-ECT treatment in patients with schizophrenia, a study shows.

Sleep Disorders May Raise Risk for Sudden Death in Epilepsy

Comorbid primary sleep disorders are tied to higher risk for sudden unexpected death, all-cause mortality, and accidents in patients with epilepsy, a new study finds.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

Ocular motor cranial neuropathy is associated with an increased risk for Parkinson’s disease, a new study shows.

Traumatic brain injury is bidirectionally associated with the incidence of stroke, dementia, epilepsy, and Parkinson’s disease, a retrospective study shows.

Targeted interventions, especially avatar therapy, are associated with less severe auditory hallucinations in patients with schizophrenia, a new meta-analysis shows.

In a small feasibility study, a novel adaptive DBS system synchronized with the walking cycle has been shown to reduce the risk for falls among patients with Parkinson’s disease.

Electroconvulsive therapy (ECT) is associated with longer time to hospital readmission or suicide compared to non-ECT treatment in patients with schizophrenia, a study shows.

Comorbid primary sleep disorders are tied to higher risk for sudden unexpected death, all-cause mortality, and accidents in patients with epilepsy, a new study finds.

News All Time

Brief Brain Stimulation Effective for Depression in PD

Intermittent theta-burst stimulation matches the efficacy of standard transcranial magnetic stimulation for depression in Parkinson’s disease but with a shorter treatment time, new research shows.

AD Biomarkers Tied to Worse Cognition in Midlife Adults

Alzheimer’s disease pathology, measured by amyloid and tau blood biomarkers, can appear in midlife and is associated with worse cognitive performance years before dementia onset.

Lumateperone Linked to Lower Risk for Schizophrenia Relapse

Lumateperone was associated with a 63% lower risk for relapse and was well-tolerated among patients with schizophrenia.

CMS Rule Misses Mark on CPAP Adherence

A Kaiser Permanente study shows some people who initially struggle with CPAP adherence still use the device at 1 year, suggesting CMS’ 90-day cutoff is too strict.

New Imaging Agent Could Speed Detection of AD-Related Tau

A novel PET imaging agent identified AD-related tau earlier and in more patients than the currently used tracer, possibly speeding AD detection, a new study shows.

Federally Funded Research Backs Tighter Drinking Limits

A federally funded review conducted to inform US dietary advice supports a one-drink-per-day limit for all adults — a stricter recommendation than current federal guidance.

Melatonin Gummies Blur Line Between Medicine and Candy

Pediatricians call for a ban on melatonin gummy bears and similar products, warning that candy-like supplements may encourage unsupervised use in children.

A New Option for Headache?

Findings come from a single-center study suggest the non-opioid suzetrigine may help reduce pain in multiple headache types, but more research is needed.

Most ‘Sleep-Divorced’ Couples Support Sleeping Separately

A study in Brazil reveals the prevalence and attitudes among couples not driven by relationship stress toward ‘sleep divorce’ arrangements.

NfL a Biomarker for Cognitive Function in Patients With MS?

New data offer strong evidence that neurofilament light chain (NfL) levels could be an accurate biomarker for monitoring cognitive function in MS.

Experimental Drug Cuts Migraine Days in Mid-stage Trial

Denmark's Lundbeck said on Thursday its experimental drug bocunebart cut monthly migraine days in ⁠a mid-stage study, supporting further development of a new type of...

Spinal Cord Treatment Triggers Hope and Lawsuits in Brazil

An experimental treatment for spinal cord injuries is drawing patients from as far as Mexico, mobilizing the government to expedite approval before its safety has been proven in a clinical trial.

Global Lewy Body Dementia Incidence: New Data

The first known analysis of pooled worldwide population-based data on dementia with Lewy bodies shows incidence is higher than that of other uncommon neurological disorders.

Comorbid Illness Common in Functional Neurologic Disorder

Functional neurologic disorder has a higher mortality rate than multiple sclerosis and often occurs with comorbid neurologic and psychiatric disorders, a new study shows.

First Clear Win for BTK Inhibitors in Relapsing MS

After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active comparator for relapsing MS outcomes.

Primary Care Making More Mental Health Diagnoses for Kids

Pediatric mental health visits in primary care surged over a 9-year period.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot